| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT04447768 |
| P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
| P767 | contributor to the creative work or subject | Genentech | Q899140 |
| P17 | country | United States of America | Q30 |
| P582 | end time | 2022-07-01 | |
| P1050 | medical condition | leukemia | Q29496 |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 100 | |
| P4844 | research intervention | obinutuzumab | Q389496 |
| venetoclax | Q23671272 | ||
| P6153 | research site | Memorial Sloan Kettering Cancer Center | Q1808012 |
| P8005 | research subject recruitment status | not yet recruiting | Q76649614 |
| P859 | sponsor | Memorial Sloan Kettering Cancer Center | Q1808012 |
| P580 | start time | 2020-07-01 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting |
Search more.